Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

Nebulized treprostinil (Tyvaso) reduced lung function decline from idiopathic pulmonary fibrosis (IPF) in the pivotal TETON-1 ...

Guiding people on how to correctly use inhaled medications via a phone-based program can help improve technique, according to a new study in the March 2026 issue of Chronic Obstructive Pulmonary ...

Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, affects more than 30 million Americans and is the fourth leading cause of death worldwide. Many people ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...

Please provide your email address to receive an email when new articles are posted on . Several clinicians expressed concern about inhaler costs for those with COPD in January. AstraZeneca, Boehringer ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...